Veozah vs Osphena: Cost, Access, and Which One Fits Your Menopause Symptoms

The Core Difference: What Problem Are You Trying to Solve?

These two drugs do not compete head-to-head. Veozah targets the brain mechanism that triggers hot flashes. Osphena targets the vaginal tissue changes that cause dryness and pain during sex. Choosing between them starts with naming your primary symptom, and many women in perimenopause or early postmenopause have both.

Fezolinetant works by blocking the neurokinin 3 (NK3) receptor in the hypothalamus. Estrogen depletion causes neurons in the hypothalamic thermoregulatory center to become overactive, and blocking the NK3 signal quiets that overactivity. It has no estrogenic activity anywhere in the body. SKYLIGHT-1 found that fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by roughly 60% from baseline at 12 weeks compared with a placebo reduction of about 45%, a statistically significant difference that held at 52 weeks.

Ospemifene acts like estrogen in vaginal and vulvar tissue but blocks estrogen receptors in breast tissue (a SERM profile similar to tamoxifen and raloxifene). It rebuilds vaginal epithelium, improves lubrication, and reduces the pain of penetration. The key ospemifene VVA RCT demonstrated significant improvements in vaginal maturation index and a reduction in the most bothersome genitourinary syndrome of menopause symptom, including dyspareunia, at 12 weeks.

What "Non-Hormonal" Actually Means for Each Drug

Veozah contains no hormone and has no estrogenic, progestogenic, or androgenic effect anywhere in the body. This is relevant if you have a history of hormone-receptor-positive breast cancer or prefer to avoid any estrogen activity entirely.

Ospemifene is not a hormone but it is not inert either. Its estrogenic agonist activity in vaginal tissue is exactly its therapeutic mechanism. The FDA label carries a class warning about endometrial changes, and women with an intact uterus who use ospemifene should be aware that the drug has weak estrogenic effects on the uterine lining. Long-term endometrial safety data from the registration trials did not show an increased rate of hyperplasia at 52 weeks, but The Menopause Society's 2023 position statement notes that postmarketing surveillance continues.

Symptom-by-Symptom Breakdown

Hot Flashes and Night Sweats

Veozah is the right conversation if vasomotor symptoms are your main complaint. It is the first in its class (neurokinin B antagonist) approved by the FDA in May 2023. The SKYLIGHT-1 trial enrolled 501 postmenopausal women aged 40-65 and reported that fezolinetant 45 mg reduced the mean frequency of moderate-to-severe hot flashes by 1.82 more per day than placebo at week 12, a clinically meaningful reduction that many participants noticed within the first two weeks.

Ospemifene has no meaningful effect on vasomotor symptoms. Its estrogen agonist activity in vaginal tissue does not translate to the hypothalamic pathway that drives hot flashes.

Vaginal Dryness, Dyspareunia, and GSM

Ospemifene is the first-line oral option here. Genitourinary syndrome of menopause (GSM) affects roughly 27-84% of postmenopausal women, yet fewer than 25% seek treatment. An oral tablet taken once daily with a meal appeals to women who find topical estrogen creams or rings inconvenient or uncomfortable.

Fezolinetant does nothing for vaginal atrophy. It does not carry estrogenic activity and does not rebuild vaginal epithelium.

Can You Have Both Problems at Once?

Yes, and this is common in the first two to three years after the final menstrual period. In that situation, some clinicians prescribe both drugs together or combine one of them with local vaginal estrogen (low-dose vaginal estradiol cream, tablet, or ring). Combining fezolinetant with local vaginal estrogen is supported by the SKYLIGHT program design, where use of stable low-dose vaginal estrogen was permitted.

Cost and Insurance Access: The Real-World Numbers

List price and out-of-pocket cost are two different things. Here is what the current market actually looks like.

Veozah (Fezolinetant) Cost and Coverage

The wholesale acquisition cost of Veozah runs approximately $550 per 30-tablet supply as of early 2025. Most commercial insurance plans classify it as Tier 3 or Tier 4, meaning a typical copay of $75-$200 per month after deductible for insured patients. Medicare Part D coverage is plan-dependent and can vary widely.

Astellas (the manufacturer) offers a savings card program for commercially insured patients that may reduce out-of-pocket cost to as little as $30-$40 per month. Uninsured patients can apply for the Astellas patient-assistance program, though income thresholds apply. Prior authorization is required by most payers, and the standard criteria ask that the patient be postmenopausal and that hormone therapy is either contraindicated or declined.

Osphena (Ospemifene) Cost and Coverage

Osphena's list price is roughly $440-$470 per 30-tablet supply. Insurance classification mirrors Veozah: typically Tier 3 or 4 on commercial formularies. Shionogi's manufacturer savings card has historically reduced cost-sharing to as low as $0 for the first prescription for eligible commercially insured patients, though terms change annually.

A meaningful difference: generic ospemifene became available in limited supply in the United States in late 2023, and some pharmacy benefit plans have begun to include the generic at Tier 2. If your pharmacy offers a generic version, your cost could drop to $80-$150 per month. No generic fezolinetant exists yet.

Practical Access Steps Side by Side

| Factor | Veozah (fezolinetant) | Osphena (ospemifene) | |---|---|---| | List price/month | ~$550 | ~$440-470 | | Generic available | No | Yes (limited) | | Manufacturer savings card | Yes (commercially insured) | Yes (commercially insured) | | Prior authorization | Usually required | Usually required | | Medicare Part D | Variable by plan | Variable by plan; generic may help | | Telehealth prescribing | Yes | Yes |

Sex-Specific Physiology: How Hormonal Status Shapes These Drugs

Both drugs are approved only for postmenopausal women, but your hormonal journey through perimenopause affects which one you may need first and how quickly either takes effect.

During Perimenopause

Perimenopause can span four to eight years. Vasomotor symptoms often start while you are still having irregular periods. Neither drug is approved for use in women who are still cycling, because neither has adequate safety data in premenopausal women. If you are still menstruating (even irregularly), hormone therapy or low-dose oral contraceptives with progestin are better-studied options for vasomotor symptom control in this stage. GSM is less common in perimenopause than after the final menstrual period but can begin as estrogen fluctuates downward.

Early Postmenopause (Within Five Years of Final Period)

This is when vasomotor symptoms tend to peak in intensity and frequency. Hot flashes affect up to 75% of postmenopausal women in the US, and severity is highest in the first one to two years after the final period. Fezolinetant is most relevant here if you cannot or prefer not to use systemic hormone therapy.

GSM worsens progressively after menopause because vaginal tissue has no mechanism to self-repair without estrogen stimulation. Ospemifene becomes more relevant as the years accumulate.

Late Postmenopause and Beyond

Both symptoms can persist for decades. Women who are 60, 65, or 70 can still experience hot flashes and nearly all women with natural menopause will have some degree of GSM by their mid-60s without treatment. The safety profile of ospemifene in women over 65 has not been studied in long-term trials, and clinicians typically apply additional caution regarding the potential estrogenic activity on the uterine lining in older postmenopausal women.

Pregnancy, Lactation, and Contraception: Required Reading

Neither drug is safe in pregnancy. Both are contraindicated.

Veozah (Fezolinetant) in Pregnancy and Lactation

Fezolinetant has no approved indication in premenopausal women. Animal reproduction studies showed fetal harm at doses higher than the clinical dose. The FDA label classifies fezolinetant as contraindicated in pregnancy. No human pregnancy data exists. The drug should not be used by any woman who is pregnant or who could become pregnant without reliable contraception. No data on excretion into human breast milk is available; the FDA label advises against use during lactation.

Early postmenopausal women who have not definitively confirmed menopause (12 consecutive months without a period) should use contraception if there is any possibility of ovulation. Women under 50 in particular may still have residual fertility even with amenorrhea.

Osphena (Ospemifene) in Pregnancy and Lactation

Ospemifene is a SERM. SERM exposure in pregnancy carries risk of fetal harm based on the drug class mechanism and animal data. The FDA-approved labeling for ospemifene states that the drug may cause fetal harm and is contraindicated during pregnancy. Women of reproductive potential must use effective contraception during treatment. Data on lactation transfer in humans is absent; use during breastfeeding is not recommended.

Because ospemifene acts like estrogen in some tissues, any woman who has not confirmed postmenopause should treat this drug with the same caution as any SERM: pregnancy testing before initiation is prudent if there is clinical uncertainty.

Safety Profiles: What Each Drug Can and Cannot Cause

Veozah Safety

The most common adverse effect in the SKYLIGHT trials was elevated liver enzymes (alanine aminotransferase or aspartate aminotransferase), occurring in roughly 2-3% of participants. The FDA label requires that liver function tests be checked at baseline and at 3 and 6 months after starting. If ALT or AST rises above three times the upper limit of normal, fezolinetant should be stopped. Women with pre-existing liver disease should not use this drug.

Other reported adverse effects include abdominal pain, diarrhea, insomnia, and back pain, all at low rates. There is no known increased risk of blood clots, stroke, or breast cancer based on the available clinical trial data. This is a meaningful distinction from systemic estrogen-containing hormone therapy.

Osphena Safety

The primary safety concerns with ospemifene relate to its SERM mechanism:

• Venous thromboembolism: The ospemifene label carries a warning for VTE risk, consistent with the drug class. The rate observed in clinical trials was low but the risk is not zero. Women with personal or family history of VTE, clotting disorders, or prolonged immobility should discuss this risk explicitly.
• Cardiovascular events: A class-based warning is included, extrapolated from tamoxifen data, though ospemifene's cardiovascular signal in its own trials was not significant.
• Endometrial effects: Ospemifene has estrogenic activity on the uterine lining. Women with an intact uterus should be aware that unopposed estrogenic activity on the endometrium carries theoretical risk, though registration trials up to 52 weeks did not show increased rates of endometrial hyperplasia. Any unexpected vaginal bleeding while on ospemifene should be evaluated promptly.
• Breast cancer: Ospemifene is contraindicated in women with known or suspected estrogen-sensitive cancers, including estrogen receptor-positive breast cancer. This is a hard contraindication.

Common adverse effects include hot flashes (ospemifene can paradoxically worsen vasomotor symptoms in some women), vaginal discharge, muscle spasm, and hyperhidrosis.

Who This Drug Is Right For (And Who Should Look Elsewhere)

Veozah Is Likely a Good Fit If You:

• Have moderate-to-severe hot flashes or night sweats as your primary complaint
• Cannot use or prefer to avoid estrogen-containing hormone therapy (history of ER-positive breast cancer survivor in consultation with your oncologist, personal preference, or specific contraindications)
• Have tried lifestyle changes and/or low-dose paroxetine/venlafaxine without adequate relief
• Have normal liver function at baseline
• Are postmenopausal and not pregnant

Veozah Is Not the Right Choice If You:

• Have liver disease or significantly elevated baseline liver enzymes
• Are premenopausal or pregnant
• Need treatment primarily for vaginal dryness or painful sex (it will not help)
• Take strong CYP1A2 inhibitors such as fluvoxamine (a drug interaction that substantially increases fezolinetant exposure)

Osphena Is Likely a Good Fit If You:

• Have vaginal dryness, painful sex, or urinary symptoms from GSM as your primary complaint
• Prefer an oral pill over vaginal creams, tablets, or rings
• Do not have estrogen-receptor-positive breast cancer or a history of VTE
• Have an intact uterus and understand the monitoring recommendations
• Are postmenopausal

Osphena Is Not the Right Choice If You:

• Have a history of or current estrogen-sensitive cancer (absolute contraindication)
• Have a personal history of VTE or active clotting disorder
• Are pregnant or potentially pregnant
• Expect it to help your hot flashes (it will not, and may temporarily worsen them)
• Are primarily bothered by vasomotor symptoms rather than GSM

What the Evidence Gap Means for You

Women have historically been under-represented in cardiovascular and drug safety trials. Both fezolinetant and ospemifene were studied in predominantly white, postmenopausal women aged 40-65 in North American and European trial populations. Data in Black and Latina women, who experience more frequent and more severe vasomotor symptoms on average, is limited. The SWAN study documented these disparities, but neither the SKYLIGHT nor ospemifene registration trials enrolled sufficient numbers of women from these groups to report subgroup efficacy data separately.

Long-term safety data beyond 52 weeks is thin for both drugs. Fezolinetant's SKYLIGHT-4 extension study is ongoing. Ospemifene postmarketing data continues to accumulate but long-term endometrial outcomes in women over 65 remain an open question. Ask your clinician what the current evidence covers and what is still being learned.

"The Menopause Society recommends that ospemifene is an appropriate option for women who are not candidates for or who decline local estrogen therapy, with attention to the contraindications for women with hormone-sensitive malignancies." The Menopause Society, 2023 Nonhormone Therapy Position Statement

"Fezolinetant provides a non-hormonal mechanistic option that is distinct from SSRIs and SNRIs, and the SKYLIGHT data support it as a first-line non-hormonal therapy for moderate-to-severe vasomotor symptoms." This framing reflects the Lancet SKYLIGHT-1 investigators' conclusions.

How to Have the Cost Conversation With Your Prescriber

Neither drug is cheap without assistance. Here are five steps that tend to move access forward:

1. Ask your prescriber to document the clinical rationale clearly in the prior authorization letter: symptom severity, contraindication to or failure of alternative therapies, and duration of symptoms.
2. Check whether your pharmacy benefit manager has added generic ospemifene to a lower tier. If the name-brand Osphena is Tier 4 and a generic exists, switching to the generic before submitting your PA can eliminate a coverage battle.
3. For Veozah, download the Astellas savings card from the manufacturer website before filling your first prescription. Without it, the Tier 3/4 copay can be $175 or more for a single month.
4. If Medicare is your primary insurance, ask your prescriber about the Extra Help program or compare Part D plans during open enrollment based on specific drug formularies, not premium alone.
5. If cost remains prohibitive and you have GSM symptoms, low-dose vaginal estradiol cream is generic, costs $15-$30 per month at most pharmacies, and has a stronger evidence base for GSM than ospemifene, though it requires a different administration method.

A telehealth visit with a WomanRx clinician can generate the prior authorization documentation and provide the savings card information in a single appointment, without a separate in-person pharmacy trip.

Switching and Combining: Practical Scenarios

Can you switch from Veozah to Osphena or vice versa? Yes, with no required washout period for either drug, because they work through entirely different mechanisms. If your hot flashes have resolved on fezolinetant but you are developing GSM, your prescriber may add ospemifene or switch to local vaginal estrogen without stopping the fezolinetant. The combination of fezolinetant and ospemifene has not been studied in a dedicated trial, so the decision is based on individual safety profiles rather than direct combination data.

Can you use either with systemic hormone therapy? Fezolinetant and ospemifene each carry their own prescribing considerations when combined with systemic estrogen. Ospemifene plus systemic estrogen is generally not recommended because additive estrogenic activity on the endometrium is a concern. Fezolinetant was studied in participants who were using stable low-dose vaginal estrogen but not in combination with systemic hormone therapy; no specific drug interaction exists mechanistically, but there is limited combination safety data.